Patents by Inventor Shoji Furusako

Shoji Furusako has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL MULTILAYER POLYMER-COATED CROSSLINKED ALGINATE GEL FIBER
    Publication number: 20240132854
    Abstract: There has been demand for an additional method for producing antibodies. The present invention provides: a polymer-coated crosslinked alginate gel fiber in which a core layer containing a crosslinked alginate gel and either antibody-producing cells (e.g., antibody-producing CHO cells) or bioactive-substance-producing cells (e.g., MIN6 cells derived from pancreatic ? cells) is coated with a cationic polymer; and a method for producing antibodies, a bioactive substance, etc., using the fiber.
    Type: Application
    Filed: December 27, 2021
    Publication date: April 25, 2024
    Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Shoji FURUSAKO, Naoto TSUDA, Tsutomu SATOH, Tomohiro NARUMI, Shingo SATO
  • Crosslinked alginic acid
    Patent number: 11932708
    Abstract: The present invention provides alginic acid derivatives represented by formula (I) and formula (II), and a novel crosslinked alginic acid obtained by carrying out a Huisgen reaction using an alginic acid derivative of formula (I) and an alginic acid derivative of formula (II). There are thereby provided novel alginic acid derivatives and a novel crosslinked alginic acid.
    Type: Grant
    Filed: December 11, 2020
    Date of Patent: March 19, 2024
    Assignee: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Shoji Furusako, Tomohiro Narumi, Tsutomu Satoh
  • ALGINIC ACID DERIVATIVE BONDED TO NONSTEROIDAL ANTI-INFLAMMATORY COMPOUND
    Publication number: 20230190943
    Abstract: Provided is water-soluble compound that can be used in a sustained-release preparation and is capable of stably releasing a fixed amount of an active ingredient in vivo by using the novel potential base material option of alginic acid as the base material.
    Type: Application
    Filed: February 2, 2023
    Publication date: June 22, 2023
    Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Shoji FURUSAKO, Isao SAKURADA
  • NOVEL CROSSLINKED ALGINIC ACID
    Publication number: 20230035986
    Abstract: Provided are novel alginic acid derivatives and a novel crosslinked alginic acid. The alginic acid derivatives are represented by formula (I) and formula (II). The novel crosslinked alginic acid obtained by Huisgen reaction using an alginic acid derivative of formula (I) and an alginic acid derivative of formula (II).
    Type: Application
    Filed: June 16, 2022
    Publication date: February 2, 2023
    Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Shoji FURUSAKO, Tsutomu SATOH, Tomohiro NARUMI
  • TRANSPLANTATION DEVICE USING CHEMICALLY CROSSLINKED ALGINIC ACID
    Publication number: 20220409773
    Abstract: Provided is a transplantation device comprising a hydrogel in which insulin-secreting cells or pancreatic islets are enclosed, wherein the hydrogel is prepared by gelatinizing an alginic acid derivative by a chemical crosslinkage. Thus, a novel transplantation device is provided.
    Type: Application
    Filed: June 26, 2020
    Publication date: December 29, 2022
    Applicants: MOCHIDA PHARMACEUTICAL CO., LTD., NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE
    Inventors: Masayuki SHIMODA, Kumiko AJIMA, Shoji FURUSAKO
  • NOVEL CROSSLINKED ALGINIC ACID STRUCTURE
    Publication number: 20220396643
    Abstract: Provided are a novel crosslinked alginic acid, a crosslinked alginic acid structure, etc., by performing a crosslinking reaction using alginic acid derivatives represented by formula (I) and formula (II). As a result, a novel crosslinked alginic acid, crosslinked alginic acid structure, etc., are provided.
    Type: Application
    Filed: September 24, 2020
    Publication date: December 15, 2022
    Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Shoji FURUSAKO, Tomohiro NARUMI, Tsutomu SATOH
  • Photocrosslinkable alginic acid derivative
    Patent number: 11472891
    Abstract: The present invention provides: an alginic acid derivative having a photocrosslinking group represented by general formula (1) for a portion of a carboxyl group of alginic acids, and a photocrosslinking alginic acid structure which is produced using this alginic acid. Due to this configuration, a novel alginic acid derivative is provided.
    Type: Grant
    Filed: February 27, 2019
    Date of Patent: October 18, 2022
    Assignee: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Shoji Furusako, Tsutomu Satoh
  • Reactive alginic acid derivatives
    Patent number: 11472892
    Abstract: The present invention provides alginic acid derivatives having a group represented by general formula (I) or general formula (II) (the right side of the dashed line is excluded in each formula) at a portion of the carboxyl groups in an alginic acid. Novel alginic acid derivatives are thereby provided.
    Type: Grant
    Filed: March 27, 2019
    Date of Patent: October 18, 2022
    Assignee: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Shoji Furusako, Tsutomu Satoh, Tomohiro Narumi
  • NOVEL PHOTOCROSSLINKABLE ALGINIC ACID DERIVATIVE
    Publication number: 20210380727
    Abstract: The present invention provides: an alginic acid derivative having a photocrosslinking group represented by general formula (1) for a portion of a carboxyl group of alginic acids, and a photocrosslinking alginic acid structure which is produced using this alginic acid. Due to this configuration, a novel alginic acid derivative is provided.
    Type: Application
    Filed: February 27, 2019
    Publication date: December 9, 2021
    Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Shoji FURUSAKO, Tsutomu SATOH
  • ALGINATE HOLLOW MICROFIBER
    Publication number: 20210340481
    Abstract: Provided are an alginate gel fiber for antibody production wherein an antibody-producing cell (for example, an antibody-producing CHO cell) is comprised in a core layer, and an antibody production method using the alginate gel fiber. An antibody production method is thereby additionally provided.
    Type: Application
    Filed: August 9, 2019
    Publication date: November 4, 2021
    Applicants: MOCHIDA PHARMACEUTICAL CO., LTD., THE UNIVERSITY OF TOKYO
    Inventors: Shoji FURUSAKO, Shoji TAKEUCHI
  • NOVEL CROSSLINKED ALGINIC ACID
    Publication number: 20210095053
    Abstract: The present invention provides alginic acid derivatives represented by formula (I) and formula (II), and a novel crosslinked alginic acid obtained by carrying out a Huisgen reaction using an alginic acid derivative of formula (I) and an alginic acid derivative of formula (II). There are thereby provided novel alginic acid derivatives and a novel crosslinked alginic acid.
    Type: Application
    Filed: December 11, 2020
    Publication date: April 1, 2021
    Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Shoji FURUSAKO, Tomohiro NARUMI, Tsutomu SATOH
  • NOVEL REACTIVE ALGINIC ACID DERIVATIVES
    Publication number: 20210024659
    Abstract: The present invention provides alginic acid derivatives having a group represented by general formula (I) or general formula (II) (the right side of the dashed line is excluded in each formula) at a portion of the carboxyl groups in an alginic acid. Novel alginic acid derivatives are thereby provided.
    Type: Application
    Filed: March 27, 2019
    Publication date: January 28, 2021
    Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Shoji FURUSAKO, Tsutomu SATOH, Tomohiro NARUMI
  • ALGINIC ACID DERIVATIVE BONDED TO NONSTEROIDAL ANTI-INFLAMMATORY COMPOUND
    Publication number: 20210000968
    Abstract: Provided is water-soluble compound that can be used in a sustained-release preparation and is capable of stably releasing a fixed amount of an active ingredient in vivo by using the novel potential base material option of alginic acid as the base material.
    Type: Application
    Filed: September 17, 2020
    Publication date: January 7, 2021
    Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Shoji FURUSAKO, Isao SAKURADA
  • ANTI-CD14 ANTIBODY FUSION PROTEIN
    Publication number: 20140050727
    Abstract: A protein comprising (I) an anti-CD14 antibody or its active fragment, or a derivative thereof and (II) an inhibitor for a protease, or its active fragment, or a derivative thereof is provided.
    Type: Application
    Filed: August 21, 2013
    Publication date: February 20, 2014
    Applicant: Mochida Pharmaceutical Co., Ltd.
    Inventors: Shoji FURUSAKO, Kazuyuki NAKAYAMA, Yoshitaka HOSAKA, Tetsushi KAWAHARA, Masaki NAKAMURA, Takashi TAKEUCHI
  • ANTI-PLATELET MEMBRANE GLYCOPROTEIN VI MONOCLONAL ANTIBODY
    Publication number: 20140044723
    Abstract: The present invention provides an antibody which has the following features, its active fragment, or a derivative thereof: a) It specifically binds to human platelet membrane glycoprotein VI (GPVI); b) The function to activate a platelet and/or the function to induce a thrombocytopenia in vivo are low; and c) It at least partially depletes GPVI on the platelet membrane by contacting with a platelet.
    Type: Application
    Filed: July 24, 2013
    Publication date: February 13, 2014
    Inventors: Hiroshi Takayama, Kamon Shirakawa, Shoji Furusako, Yoshitaka Hosaka, Tomokazu Matsusue, Katsuki Naitoh, Yumi Hotta, Tetsushi Kawahara, Motoyasu Honda
  • Polynucleotide encoding anti-CD14 antibody fusion protein
    Patent number: 8541565
    Abstract: A protein comprising (I) an anti-CD14 antibody or its active fragment, or a derivative thereof and (II) an inhibitor for a protease, or its active fragment, or a derivative thereof is provided.
    Type: Grant
    Filed: July 12, 2012
    Date of Patent: September 24, 2013
    Assignee: Mochida Pharmaceutical Co., Ltd.
    Inventors: Shoji Furusako, Kazuyuki Nakayama, Yoshitaka Hosaka, Tetsushi Kawahara, Masaki Nakamura, Takashi Takeuchi
  • Anti-platelet membrane glycoprotein VI monoclonal antibody
    Patent number: 8524870
    Abstract: The present invention provides an antibody which has the following features, its active fragment, or a derivative thereof: a) It specifically binds to human platelet membrane glycoprotein VI (GPVI); b) The function to activate a platelet and/or the function to induce a thrombocytopenia in vivo are low; and c) It at least partially depletes GPVI on the platelet membrane by contacting with a platelet.
    Type: Grant
    Filed: December 20, 2012
    Date of Patent: September 3, 2013
    Assignee: Mochida Pharmaceutical Co., Ltd.
    Inventors: Hiroshi Takayama, Kamon Shirakawa, Shoji Furusako, Yoshitaka Hosaka, Tomokazu Matsusue, Katsuki Naitoh, Yumi Hotta, Tetsushi Kawahara, Motoyasu Honda
  • Anti-platelet membrane glycoprotein VI monoclonal antibody
    Patent number: 8389692
    Abstract: The present invention provides an antibody which has the following features, its active fragment, or a derivative thereof: a) It specifically binds to human platelet membrane glycoprotein VI (GPVI); b) The function to activate a platelet and/or the function to induce a thrombocytopenia in vivo are low; and c) It at least partially depletes GPVI on the platelet membrane by contacting with a platelet.
    Type: Grant
    Filed: April 27, 2011
    Date of Patent: March 5, 2013
    Assignee: Mochida Pharmaceutical Co., Ltd.
    Inventors: Hiroshi Takayama, Kamon Shirakawa, Shoji Furusako, Yoshitaka Hosaka, Tomokazu Matsusue, Katsuki Naitoh, Yumi Hotta, Tetsushi Kawahara, Motoyasu Honda
  • ANTI-CD14 ANTIBODY FUSION PROTEIN
    Publication number: 20120277412
    Abstract: A protein comprising (I) an anti-CD14 antibody or its active fragment, or a derivative thereof and (II) an inhibitor for a protease, or its active fragment, or a derivative thereof is provided.
    Type: Application
    Filed: July 12, 2012
    Publication date: November 1, 2012
    Inventors: Shoji FURUSAKO, Kazuyuki Nakayama, Yoshitaka Hosaka, Tetsushi Kawahara, Masaki Nakamura, Takashi Takeuchi
  • Anti-CD14 antibody fusion protein
    Patent number: 8252905
    Abstract: A protein comprising (I) an anti-CD14 antibody or its active fragment, or a derivative thereof and (II) an inhibitor for a protease, or its active fragment, or a derivative thereof is provided.
    Type: Grant
    Filed: June 5, 2006
    Date of Patent: August 28, 2012
    Assignee: Mochida Pharmaceutical Co., Ltd.
    Inventors: Shoji Furusako, Kazuyuki Nakayama, Yoshitaka Hosaka, Tetsushi Kawahara, Masaki Nakamura, Takashi Takeuchi